Lavipharm S.A. (ATH:LAVI)

Market Cap	135.96M
Revenue (ttm)	52.95M
Net Income (ttm)	8.98M
Shares Out	168.69M
EPS (ttm)	n/a
PE Ratio	15.14
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	85,855
Average Volume	196,518
Open	0.7980
Previous Close	0.8010
Day's Range	0.7980 - 0.8200
52-Week Range	0.7060 - 1.0100
Beta	1.22
RSI	48.76
Earnings Date	Mar 24, 2025

About Lavipharm

Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, dermocosmetic, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD. The company was founded in 1911 and is based in Paiania, Greece.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1911
• Employees: 307
• Stock Exchange: Athens Stock Exchange
• Ticker Symbol: LAVI

Financial Performance

In 2024, Lavipharm's revenue was 52.95 million, an increase of 3.96% compared to the previous year's 50.93 million. Earnings were 8.98 million, an increase of 379.90%.